当前位置: X-MOL 学术Bioengineered › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses.
Bioengineered ( IF 4.9 ) Pub Date : 2020-02-29 , DOI: 10.1080/21655979.2020.1736755
Zhonghua Chen 1, 2 , Xiaoli Guo 3 , Shukai Sun 4 , Caixia Lu 1 , Liming Wang 1
Affiliation  

Downexpression of miRs was associated with tumor development, progression, and metastasis. This study explored the serum levels of miR-125b in patients with epithelial ovarian cancer (EOC) and to assess its diagnostic value and monitor treatment responses for patients with EOC. A total of 379 individuals were recruited and assigned to the study groups. RT-qPCR analysis was performed to confirm the association of serum miR-125b levels with tumor stages and treatment responses. The median serum levels of miR-125b in patients with EOC were significantly lower than that of other controls (P < 0.0001). Serum miR-125b in patients with high FIGO stage (III+IV), lymph node metastasis, and chemoresistance were lower than that in patients with early-stage (stage I+ II; P < 0.001), without lymph metastasis (p = 0.032) and chemosensitivity (P < 0.001). Low levels of miR-125b had a poor prognosis in patients with EOC. Using a median value of 0.748 to separate EOC from other controls, the sensitivity and specificity reached 0.76 (95% CI 0.75 to 0.85) and 0.416 (95% CI 0.26 to 0.55), respectively. Serum miR-125b showed a statistically significant difference between preoperative and postoperative patients in surgical patient groups (P = 0.003). Serum miR-125b levels were lower in patients with chemoresistance than that in patients with chemosensitivity (P < 0.0001). Serum miR-125b in combination with serum CA125 improved both sensitivity and specificity in diagnosis of EOC (P < 0.001). This study demonstrated that serum miR-125b levels were a useful diagnostic biomarker and biomarker to predict the responses to chemotherapy in patients with EOC.

中文翻译:

血清miR-125b水平与上皮性卵巢癌(EOC)的发展和治疗反应有关。

miRs的低表达与肿瘤的发生,发展和转移有关。这项研究探讨了上皮性卵巢癌(EOC)患者的miR-125b血清水平,并评估其诊断价值并监测EOC患者的治疗反应。总共招募了379个人,并分配给了研究组。进行RT-qPCR分析以确认血清miR-125b水平与肿瘤分期和治疗反应之间的关系。EOC患者的miR-125b血清中值显着低于其他对照组(P <0.0001)。FIGO期高(III + IV),淋巴结转移和化学耐药的患者的血清miR-125b低于无淋巴转移的早期阶段(I + II; P <0.001)的患者(p = 0.032)和化学敏感性(P <0.001)。低水平的miR-125b在EOC患者中预后较差。使用0.748的中值将EOC与其他对照区分开,灵敏度和特异性分别达到0.76(95%CI 0.75至0.85)和0.416(95%CI 0.26至0.55)。在手术患者组中,术前和术后患者的血清miR-125b差异具有统计学意义(P = 0.003)。化学抗性患者的血清miR-125b水平低于化学敏感性患者(P <0.0001)。血清miR-125b与血清CA125的结合可提高EOC诊断的敏感性和特异性(P <0.001)。这项研究表明,血清miR-125b水平是有用的诊断生物标志物和生物标志物,可预测EOC患者对化疗的反应。
更新日期:2020-05-06
down
wechat
bug